Florian Wagenlehner

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Vifor Pharma
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Sysmex
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Spero
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Shionogi
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    SelectImmune Pharma AB
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Rosen Pharma
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Rempex
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Qiagen
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (General Urology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    OM-Pharma
    Date added:
    Date updated:
    06/29/2022

Pages

Return to Update Series (2022) Lesson 21: The Changing Role of Fluoroquinolones for Prophylaxis and Treatment of Urological Infections